newsfilter
← Latest News
PR Newswire·

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

BETHESDA, Md., May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate